Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

MSC secretomes as a cell-free therapeutic platform: Molecular heterogeneity, disease-specific bioactivity, delivery strategies, and regulatory translation across six major disease areas.

Negrete-Diaz F., Martinez-Rodriguez S., Guedan-Duran A., Romero-Lopez A., Panetsos F.

Narrative Review on Chronic Inflammation, Immune Modulation, published in Pharmacol Res (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Pharmacol Res (2026)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
42140327
DOI
10.1016/j.phrs.2026.108245

Abstract (original English)

The mesenchymal stromal/stem cell (MSC) secretome is emerging as a cell-free pharmacological agent with multitarget activity in regenerative and inflammatory diseases. Rather than durable engraftment or differentiation, most therapeutic effects of MSC-based therapies are mediated by a complex mixture of soluble factors and extracellular vesicles (EVs) that can, in principle, be formulated as standardized biological drugs. This review appraises current evidence on MSC secretome composition, mechanisms of action, and pharmacological profile, emphasizing its potential as a scalable off-the-shelf platform. We first characterize the source-dependent architecture of the MSC secretome derived from bone marrow, adipose tissue, and umbilical cord, identifying a conserved core of 894 shared proteins alongside tissue-specific signatures that determine differential bioactivity. Pharmacologically active components are classified by mechanism, encompassing anti-inflammatory, pro-angiogenic, neuroprotective, antifibrotic, and regenerative mediators. We then critically examine preclinical evidence for secretome- and EV-based interventions across cardiovascular, neurological, ocular, inflammatory, musculoskeletal, and dermatological diseases, comparing mechanistic profiles, delivery routes, and potential advantages over current standard-of-care therapies. Finally, we address key translational c

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
HumansAnimalsMesenchymal Stem CellsSecretomeExtracellular VesiclesTranslational Research, Biomedical

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research